Erlotinib and Avastin in Patients With Cancer of the Esophagus or Gastroesophageal Junction
Status:
Terminated
Trial end date:
2009-01-01
Target enrollment:
Participant gender:
Summary
Determine the time to progression for the combination of erlotinib and bevacizumab in
patients with previously treated metastatic cancer of the esophagus or gastroesophageal
junction